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ABSTRACT 
The vaginal course of medication conveyance offers many focal points because of its huge permeation range, rich vascularization, 
avoidance of first pass metabolism and relatively low enzymatic activity. A few examinations have demonstrated that for sedate 
organization the vaginal pit is a viable course which expected for the most part for neighborhood activity and conveying drugs for 
foundational impacts with uterine focusing on. It was first Sobrero who endeavored the vaginal mucosa for tranquilize 
assimilation, from that point forward much research has been done on the organization of medications through this course. As of 
late, for vaginal dose frame, different plan and application has expanded impressively. It is fundamentally the conveyance of 
medications inside or through the vaginal mucosa for neighborhood or foundational pharmacological activity. Degree of 
medication ingestion and its rate after organization may shift contingent upon vaginal physiology, age of the patient, arrange in the 
menstrual cycle, neurotic conditions and detailing factors. Here in this audit, there's a feature, the advantages and confinements of 
vaginal medication conveyance, philosophy in assessment of vaginal medication conveyance frameworks, pharmaceutical 
viewpoints and an outline of late advances made in the bailiwick of vaginal medication conveyance. Advancement of 
measurements frame in various stages and in the market, are likewise audited. 
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INTRODUCTION 
Novel researchers have shown their interest on 
mucoadhesive drug delivery systems among them; 
vaginal drug delivery system offers a thoroughfare for 
the release of different antifungal, antibacterial and 
contraceptive drugs. To improve the vaginal therapy, 
the formulation administered via the vagina should 
have more residence time in the vaginal cavity. 
Conventional vaginal dosages forms have pros and 
cons both, like they avoid the first pass metabolism, 
easy to formulate, self-administration, and are 
economical whereas it produces itching, irritation of 
vagina, messy to apply, and low residence time 
respectively. Therefore, to overcome nano drug 
delivery systems are being formulated. Recently nano 
drug delivery systems like vaginal liposomes, vaginal 
niosomes, nano suspensions, nano emulsions, 
nanofibres, have evoked more interest to deliver the 
drugs via the vaginal route. They offer increased 
residence time, cellular targeting, localization of 
formulation to specific sites and mucoadhesion. 
Various mucoadhesive polymers like hydroxylpropyl 
methylcellulose (HPMC), chitosan, sodium alginate, 
eudragit, polycarbophil, carrageenan, hydroxypropyl 
cellulose, ethylene (vinyl acetate) co- polymer among 
others have been used for developing novel vaginal 
formulations. For prevention of HIV and other sexually 
transmitted diseases (STDs)
1
 topical delivery of 
microbicides is also being investigated as an alternative 
option. 
Merits of bioadhesive systems over the existing 
conventional preparations:  
 Excellent accessibility2 
 Avoidance of aqueous or organic solvents,  
  Easy of self-administration3   
  Gel like consistency in the activated state or at the 
body temperature
4
  
  No irritation  
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  Rapid bioadhesion, prolonged residence time in the 
vaginal cavity even in absence of physiological 
secretions
5
.   
 Extended dosing interval6.  
 Improved chemical and physical stability7. 
Mucoadhesive vaginal delivery systems have both 
synthetic and natural polymers. Most commonly used 
mucoadhesive polymers that are capable of forming 
hydrogels are synthetic polycarbophil, chitosan, 
cellulose derivatives (hydroxyethycellulose, 
hydroxypropyl cellulose and hydroxypropyl 
methylcellulose), pectin, hyaluronic acid derivatives, 
polyacrylates, tragacanth, carrageenan and sodium 
alginate.  New mucoadhesive molecules are thyolated 
polymers. There bioadhesive properties are cinched by 
polyacrylic acid-based polymers, known as Carbomers.  
Mercantilelycarbomers are available in different grade, 
molecular weight, residual component or degree of 
cross-linked structure. Among these polymers, 
polycarbophil and polyacrylic acid are cross-linked 
with divinylglycol and are more preferred also. These 
water insoluble polymers have an apparent pKa of 
approx 4 and picks up 61-100 times its weight in 
water
8-10
. 
Disadvantages  
 Gender specificity,                                                                                                                        
 Patient incompliance,                                                                                                                       
 Only a few drugs are administered by this 
route
11
. 
 Variability in drug absorption related with 
menstrual cycle, menopause and pregnancy,           
 Influence with sexual intercourse12. 
 Personal hygiene.  
 Some drugs are sensitive at vaginal pH13. 
 
ANATOMY AND PHYSIOLOGY OF VAGINA  
The human vagina is a fibro muscular tube which is 
capable of collapsing. It is a passageway that connects 
the cervix, which is the opening of the uterus, to the 
outside of the body. It is also known as the birth canal. 
The length of the vagina is 6-10 cm which widens from 
the cervix
14
. The wall of human vagina comprises of 
three layers such as: 
 An outer adventia layer. 
 Middle muscular layer. 
 The tunica adventia.  
It has contours called rugae at the walls of vagina in 
close juxtaposition to each other which form a 
collapsible tube. The epithelium portion does not 
contain any glands, but its surface is kept moist due to 
cervical secretion, whose composition and volume 
varies with age, stage of menstrual cycle and degree of 
sexual excitement. Drug absorbed via the vaginal route 
which avoids first pass metabolism because the blood 
leaving from human vagina directly enter into 
peripheral system through different veins. The normal 
human vagina lumen has an acidity of around pH 4-5. 
This vaginal pH is due to the active secretion of 
ovarian hormones and is also invariantly maintained by 
the sloughing of mature cells in the upper layers of 
vaginal mucosa. Due to the influence of estrogen, these 
cells contain a content of glycogen, which is 
metabolized to lactic acid in the vaginal canal which 
maintain the vaginal pH on the acidic side, whereas, 
the acyclic luteal influence on the vaginal mucosa 
significantly increases the pH value. 
 
VAGINAL ANATOMY AND PHYSIOLOGY 
WITH RESPECT TO DRUG DELIVERY 
The vaginal secretion, pH, enzyme activity and 
microflora makes the vagina remarkably linguistics. 
These factors affect formulation spreading, retention, 
absorption and drug release in vagina.   
Vaginal Secretions: The release is a blend of 
numerous emissions that is gathered in the vagina from 
peritoneal, follicular tubal, uterine, Bartholin's and 
Skene's organs.
15
 Here in nearness of dampness, strong 
dose plans ought to be in a perfect world scattering in 
the vaginal trench instantly after inclusion to maintain 
a strategic distance from bother to the clients. 
Catalyst Activity: The particular enzymatic action 
diminishes arranged by four diverse amino peptidases 
in vaginal homogenates i.e.: sheep > guinea pig > 
rabbit ≥ human ≥ rodent.16 The human genital tract has 
bring down enzymatic action which prompts less 
debasement of protein and peptide sedates in the 
vagina than the gastrointestinal tract. 
Vaginal pH: The pH of the healthy female genital tract 
is acidic (pH 3.5–4.5) and is maintained within that 
range by conversion of glycogen from exfoliated 
epithelial cells to lactic acid through bacteria
17
.
 
Changes in the pH are with age, stage in the menstrual 
cycle, infections, estrogen levels and variations in the 
levels of cervical mucus. A successful vaginal drug 
delivery is a critical factor for controlling the vaginal 
ph
18
. 
The change in hormone levels with age, during 
intercourse and various phases of the menstrual cycle 
leads to alteration in vaginal secretion, pH, enzyme 
activity as well as changes in the thickness and 
permeability of the epithelium all of which complicate 
the problem of achieving consistent drug delivery
[19]
. 
 
MECHANISM 
The mechanism of mucoadhesion is generally based 
into two steps;  
 Contact stage 
 Consolidation stage.  
The first stage is an intimate contact, formed between 
the mucoadhesive and mucous membrane. Initially its 
contact with the mucus layer is deep.  While in the 
consolidation stage, presence of moisture activates the 
mucoadhesive material. System is plasticized by 
moisture and allowing the mucoadhesive molecules to 
break free and attached by weak Vander Waals and 
hydrogen bonds. The diffusion theory and the 
dehydration theory are the two theories that explain the 
consolidation step.  Mucoadhesive molecules and the 
glycoproteins of the mucus mutually interact and 
interpenetration their chains and the building of 
secondary bonds. This is performed according to 
diffusion theory. For this to take place, the 
mucoadhesive device favored both chemical and 
mechanical interactions. For example, molecules 
having hydrogen bonding groups (-OH, -COOH), high 
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molecular weight, an anionic surface charge, flexible 
chains and surface-active properties, which helps in 
spreading throughout the mucus layer
20-29
. 
Theories Mucoadhesive is a complex process having 
numerous theories; their mechanisms are explained as 
below:  
Wetting Theory: The wetting theory is the oldest 
theory of adhesion. Applied on low-viscosity bio 
adhesive or liquid systems which present affinity to 
spread over the surface. Predominantly applicable to 
liquid bioadhesive systems. The thermodynamic work 
of adhesion is a function of surface tension of the 
surface in contact as well as interfacial tension.  The 
interfacial energy is responsible for the contact 
between the two surfaces and adhesive strength. By 
using measuring techniques such as the contact angel, 
liquids are spread over the surface and leads to the 
greater affinity. There is no contact angle to provide 
good spread ability. The spread ability coefficient 
(SAB) can be calculated by the difference between the 
surface energies γB and γA and the interfacial energy 
γAB. Hence this theory tells about the importance of 
contact angle and reduces the surface and interfacial 
energies to gain good amount of mucoadhesion.  
SAB = γB – γA – γAB 
Dispersion Hypothesis: Here the polymer chains and 
bodily fluid blend to an adequate profundity to make a 
semipermant cement security. Attachment compels 
increments with the level of infiltration of the polymer 
chains and dissemination coefficient have property to 
improve/diminish the entrance rate of dispersion, 
adaptability. Nature of the mucoadhesive chains, 
versatility and contact time likewise rely upon 
dispersion coefficient. Profundity of interpenetration 
required to create a productive bioadhesive security lies 
in the range 0.2-0.5. Given condition is utilized to 
identify the interpenetration profundity of polymer and 
mucin chain.  
l = (tDb) 
Where t is the contact time and D expressed asthe 
diffusion coefficient of the mucoadhesion material in 
the mucus. To achieve the adhesion strength of 
polymer, the depth of penetration is approximately 
equivalent to the chain size of polymers. If components 
have good mutual solubility then proper diffusion 
should be occurred. Bio adhesive and the mucus have 
similar chemical structures. If structural similarity is 
more than mucoadhesive bond is better.    
Fracture Theory: The most used theory in studies on 
the mechanical measurement of mucoadhesion is 
fractional theory. It attempts to relate the difficulty of 
separation of two surfaces after adhesion which is used 
to analyze the force required to separate two surfaces 
after adhesion is established. This force Sm is 
calculated in tests of resistance by the ratio of maximal 
detachment force Fm and the total surface area A0   
involved in the adhesive interaction.   
Sm = Fm/A0 
Since the fracture theory is used only for the force 
required to detach the parts and not used to measure 
interpenetration or diffusion of polymer chains.  It is 
used to calculate solid or semi-solid bio adhesive 
materials, in which no penetration of the polymer chain 
into the mucus layer.    
Electronic Theory: Hypothesis is used to describe that 
when when electron exchange between the bodily fluid 
and the mucoadhesive framework, bond ought to be 
happened, and through contrasts in their electronic 
structures is emerge. When electron is transfer between 
the mucus and the mucoadhesive, double layer of 
electrical charges at the mucus and mucoadhesive 
interface is formed. The net result of this process is the 
formation of attractive forces within the double layer. 
Adsorption Theory: After an initial contact between 
two surfaces, the material adheres because of surface 
forces acting between the atoms in the two surfaces. In 
this theory, adhesion is the result of various surface 
interactions (primary and secondary bonding) between 
the polymer that is adhesive on surface and mucus 
substrate. Chemisorption required forming primary 
bonds and ionic, covalent and metallic bonding play an 
important role in adhesion, which is generally 
undesirable due to their permanency. Vander walls 
forces, hydrophobic interactions and hydrogen bonding 
are responsible for formation of secondary bonds. To 
break these interactions less energy is required, they 
are the most well-known from of surface interaction in 
mucoadhesion process due to having semi-permanent 
bonds.  All these theories are involved in the different 
stages of the mucus/substrate interaction, rather than 
individual and alternative theories.  These theories are 
considered as supplementary process. Each and every 
theory is equally describing the mucoadhesion process. 
Mucin is initially wetting and then diffusion of the 
polymer into mucin layer and formation of fractions in 
the layers, the adhesion or electronic transfer or simple 
adsorption phenomenon should be affected that finally 
leads to the perfect mucoadhesion. Formation of 
mucoadhesive bond is depending on the nature of the 
mucus membrane, mucoadhesive material, the 
attachment process and the subsequent environment of 
the bond. 
 
VAGINAL ROUTES OF DRUG ABSORPTION   
The drug is delivered in the vagina mainly via two 
routes: intravaginally to the vaginal epithelium or 
transvaginal through the vaginal mucosa to uterus and 
systemic circulation. Cicinelli et al. reported that the 
vagina has specific blood flow characteristics, either by 
a portal type circulation or by venous and lymphatic 
channels that allow bypassing the gastrointestinal tract 
absorption and liver detoxification and permit 
preferential transport of drug molecules from the 
vagina to the uterus and systemic circulation.
[30]
 
Several physical models have been devised to study the 
vaginal permeability of drugs
31
.
 
Antifungal agents such 
as tioconazole, clotrimazole and miconazole are 
topically administered to treat vaginal yeast infections.  
On the basis of our knowledge of anatomical and 
physiological features of the vagina, it is likely that 
many other drugs will be formulated for vaginal 
administration in the future
32-39
.  
The vagina as a site for microbicide delivery   
Significant advance has been accounted for in the zone 
of vaginal microbicides. There are currently more than 
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50 potentially microbicidal products under 
development globally, of which 16 are in Phases I-III 
clinical trials. Recently, the vagina has been 
rediscovered as potential route for microbicide and 
contraceptive delivery. Acid form is a gel definition 
that keeps up a low vaginal pH, immobilizes sperm and 
forestalls duplication and survival of STD causing 
creatures
40-41
.
 
Cellulose acetate phthalate based sponges 
and those made from other cellulose derivatives are 
soft, mechanically resilient and thus ideally suitable as 
bio-erodible microbicidal vaginal devices
42
.
 
Conceival 
is a novel non-toxic, nonspermicidal, self                                                                                                
emulsifying lipophilic gel with improved solubility of 
lipophilic anti-HIV microbicides
43
. Another vaginal 
product under development is a liposome preparation 
containing monoclonal antibodies that will completely 
agglutinate sperm in the ejaculate.   
Pharmaceutical aspects   
Many pharmaceutical organizations right now 
concentrate on the advancement of novel vaginal 
medication conveyance frameworks for treatment of 
vaginal contaminations, sexually transmitted diseases, 
contraception and other gynecological conditions. 
These innovative delivery systems may lead to 
extended product shelf life making the products 
competitive in the market place. The option approach 
of definitions based pharmaceutical organizations is 
grow new measurements frames utilizing novel 
excipients that offer particular preferences over 
ordinary medication conveyance frameworks. With a 
specific end goal to accomplish alluring medication 
attributes diverse methodologies are utilized
44
.
 
The 
compatibility between the drug and excipients can 
easily be evaluated by thermal (Differential Scanning 
Calorimetry) and isothermal (HPLC) stress testing.
45
 
Penetration Enhancers: Penetration enhancers are 
capable of promoting absorption and penetration of 
drug through the vaginal mucosa by decreasing the 
penetration barrier
9,46
. Currently, the most preferred 
penetration enhancers include non-ionic surface-active 
agents, bile salts, benzalkonium chloride, hyaluronic 
acid
47
, polyethylene glycol, ethoxydiglycol and inter 
esterified stone oil
5, 20
. 
Solubility Modifiers: The poor solubility of drugs in 
simulated vaginal fluid may affect the release pattern 
of a drug from its device, which influences the onset 
and therapeutic efficacy of the drug. Water-soluble 
drugs are good candidates for vaginal drug delivery. 
The aqueous solubility of a drug can be increased by 
several mechanisms such as addition of solubilizing 
agents and cosolvency
48
. The most commonly used 
solubilizing agents include citric acid, 
ethylenediaminetetraacetate, sodium meta-phosphate, 
polyvinyl pyrrolidone, sorbitan, tween 80, 
polyoxyethylene, polyoxyethylene n-alkyl ethers, 
poloxamers, and cyclodextrin
49
.
 
For example, a novel 
itraconazole formulation intended for vaginal use is 
based on hydroxypropyl-β-cyclodextrin, a functional 
excipient that increases drug solubility
50
. 
Mucoadhesive agents: Mucoadhesive agents permit a 
close contact of formulation with the vaginal mucosal 
surface by promoting adherence
51
. These include 
polycarbophil, hyaluronic acid, chitosan, sodium 
alginate, tragacanth, carbomer, acacia, sodium 
carboxymethyl cellulose or other cellulose derivatives, 
Carbopol 974P-NF, Carbopol 971P-NF and other 
copolymers of acrylic acid
52
. Some of these polymers 
may possess sitespecific bioadhesive properties. For 
example, xanthan gum and sodium alginate show 
sitespecific bioadhesive properties in a simulated 
vaginal environment
53
.
 
Polycarbophil 934P exhibited 
pH-dependent bioadhesive properties
54
. 
 
CONVENTIONAL VAGINAL DOSAGE 
FORMULATIONS 
Vaginal tablet: Vaginal tablets are prepared in such a 
way that they will melt, or disintegrate in the vagina 
and release the medication in the cavity. Vaginal tablet 
contains all the excipients of a normal conventional 
tablet. The tablets are prepared by direct compression 
method and effervescing agents can be incorporated 
into formulations to enhance the swellabilty and release 
of the drug
54
. Tablets offer the advantage of ease of 
manufacture and insertion. Tablets are stable and less 
messy to handle than creams or ointments. For 
example, Clotrimazole vaginal tablet have been used to 
prevent vaginal candidiasis. Ultra-low dose estriol and 
Lactobacillus acidophilus vaginal tablets (Gynoflor®) 
were found to be effective in treating vaginal atrophy 
in postmenopausal breast cancer patients
55-58
. Bio 
adhesive vaginal tablets containing cyclodextrin 
complex of itraconazole were developed to prevent 
vaginal candidiasis. Vaginal creams are used to deliver 
the antifungal, antibacterial and contraceptive drugs 
topically
59-62
. Vaginal creams are messy to apply, 
uncomfortable and sometimes embarrassing when they 
leak into the underclothing. Also, the exact dose is not 
provided because of the heterogeneous distribution of 
the formulation when applied into the vagina as they 
are easy to use, formulate and are easily available. 
Premarin vaginal cream is indicated for the treatment 
of patients with refractory endometria
63
. Conjugated 
equine estrogen vaginal cream can be used to relieve 
menopausal atrophic Vaginitis. Bacterial vaginosis can 
be treated by clindamycin cream. Dienoestrol cream 
may be useful in the symptomatic prevention of 
vaginal atrophy in postmenopausal women. 
Postmenopousal vaginal atrophy can be treated with 
ovestin vaginal cream and estradiol vaginal cream
64
. 
Vaginal foam: Vaginal foams are contraceptive foams, 
used to prevent conception. Spermicide is added in 
vaginal foam to destroy the sperm and reduce the 
chances of pregnancy. The foam produces a partition 
between the sperm and the egg. It is very essential to 
administer the foam correctly and intercourse should be 
happening within 1h. Advantages of vaginal foams 
include availability in market and can be used as a 
lubricant during sexual intercourse. Different 
disadvantages have been reported like they produce 
messiness, not effective against other sexually 
contagious diseases, may produce inflammation, 
irritation of vagina, and should be used with other 
contraceptive device to make it effective. Vaginal froth 
containing a remedially compelling measure of 
rifaximin was observed to be helpful in the treatment of 
vaginal diseases, especially bacterial vaginosis.
64 
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Vaginal gel: Vaginal gels containing antibacterial 
drugs have been used to prevent various vaginal 
infections. They can also be used to reduce vaginal 
irritation, discharge and other sexual problems. 
Bacterial vaginosis is an infection of the vagina caused 
by overgrowth of the bacteria and this infection can be 
treated by vaginal gel
65-71
. Vaginal gels have been 
commonly used to deliver agents that tighten the 
vaginal area by contracting the vaginal muscles, 
helping in enhanced sexual pleasure. In vaginal 
dryness, gels are used as a lubricant. Some 
disadvantages of vaginal gels are that they are 
contraindicated during menstruation and pregnancy. 
They may suffer from leakiness and messiness. 
Examples: Hyaluronic acid vaginal gel can be applied 
in case of vaginal dryness. Researchers have found that 
certain vaginal gel having antiretroviral drugs may 
decrease the risk of HIV infection among women. 
Tenofovir vaginal gel has been investigated in the 
prophylaxis of HIV vaginal suppositories. There are a 
large number of vaginal suppositories in the market 
which are used to release antifungal and antibacterial 
drugs in the vagina for different vaginal infections. 
Reported advantages with vaginal suppositories include 
avoiding the first pass metabolism, ease to formulate, 
and self- administration. Different disadvantages are 
also seen like they produce messiness, less 
bioadhesion, contraindicated during pregnancy and 
other sexual problems. For example, vaginal 
suppositories with lactobacillus were formulated and 
evaluated to decrease the recurrence of urinary tract 
infections (UTI) following antimicrobial therapy. 
Progesterone vaginal suppositories were developed for 
the prevention of premenstrual syndrome. 
Prostaglandin suppositories were found to be effective 
for vaginal infection. Amphotericin B vaginal 
suppositories were developed for the treatment of non-
Candida albicans vaginitis in women. Prostaglandin E2 
vaginal suppositories were found to be efficacious in 
the treatment of persistent postpartum uterine atony. 
 
NOVEL VAGINAL DOSAGE FORMULATIONS 
Controlled/sustained release vaginal tablets 
Conventional vaginal tablets release the drug 
immediately and do not offer prolonged or controlled 
release of the drugs. Many chronic illnesses and 
recurrent infections may require prolonged therapy. 
Therefore controlled/sustained release vaginal tablets 
have been developed. These tablets may employ 
various rate sustaining polymers such as 
hydroxypropyl methylcellulose (HPMC), sodium 
carboxymethyl cellulose, sodium alginate, ethyl 
cellulose, guar gum, xanthan gum, etc. Also, the 
mucoadhesion of the tablets can be improved by using 
mucoadhesive agents such as chitosan, polycarbophil, 
etc. Tenofovir vaginal tablet was investigated to deliver 
tenofovir as a potential HIV microbicide.
72 
Vaginal ring
 
Vaginal ring is fabricated by dispersing a contraceptive 
steroid, such as medroxy progesterone acetate, as 
micronized solid particles in a viscous mixture of 
silicone elastomer and catalyst and then extruding the 
steroid polymer dispersion into a mould to form a 
vaginal ring
73-76
. They are designed to be inserted into 
the vagina and position around the cervix for 21 days 
to achieve a constant plasma progestin level and cyclic 
intravaginal contraception. Reported problem 
associated with the use of vaginal rings are erosion of 
vaginal wall, ring expulsion, interference with coitus, 
unpleasant ring odour, difficulty with storage and 
sanitation, premature discontinuation due to vaginal 
discomfort and device related events, including foreign 
body sensation. For example, Asilastic vaginal ring 
impregnated with medroxyprogesterone acetate was 
used as contraceptive device. A novel contraceptive 
vaginal ring releasing etonogestrel and ethinylestradiol 
was used to control the menstrual cycle and the 
bleeding
78
. Oestradiol releasing vaginal ring has been 
investigated for the treatment of postmenopausal 
urogenital atrophy. Novel vaginal danazol ring therapy 
for pelvic endometriosis has been investigated. Vaginal 
microspheres are designed as innovative vaginal drug 
delivery system to impart stability to drug molecules, 
improve bioavailability and to produce controlled as 
well as targeted drug release. Bioadhesive micro 
particles and mucoadhesive microspheres are used for 
better prevention of different diseases
79
. Vaginal 
microspheres have several advantages such as constant 
and prolonged therapeutic effect, mucoadhesion, 
reduction in dose frequency and better patient 
compliance. But disadvantages also have been reported 
like higher drug loading required, batch to batch non- 
uniformity, variation in release rates and toxicity
80
. 
Econazole nitrate polymer– lipid based vaginal 
mucoadhesive microspheres were prepared by using 
spray congealing method. Hyaluronan ester vaginal 
microspheres were designed for the release of salmon 
calcitonin to treat the vaginal infection. 
Vaginal nanoparticles 
Because of less duration of action and incomplete 
coverage, the effect of administered drugs via vaginal 
route reduces. Therefore, to obtain prolonged release, 
cellular targeting, and for the treatment of several 
vaginal infectious disorders, vaginal nano particles 
have been formulated. These nano particles may 
contain several mucoadhesive polymers such as 
chitosan, polycarbophil to improve the mucoadhesion 
so as to achieve better therapeutic efficacy. Example: 
mucus penetrating nano particles for vaginal drug 
delivery were used to protect against herpes simplex 
virus.
81
 Vaginal liposomes consisting small interfering 
RNA were designed to inhibit different vaginal 
infectious diseases.
82 
 
RECENT DEVELOPMENTS IN VAGINAL 
DRUG DELIVERY SYSTEM 
Vaginal films containing Abacavir, a potent nucleoside 
reverse transcriptase inhibitor, were designed for the 
inhibition of sexually transferred diseases
83
. The films 
were formulated by solvent evaporation method. The 
resulted films produce extended release of the drugs 
and they can be applied as novel drug delivery system 
for the treatment of sexually contagious diseases. 
Chitosan embedded liposomes incorporating 
clotrimazole were designed and the results showed it as 
a promising formulation for vaginal topical therapy. 
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EFdA (a proprietary topical microbicide) films were 
formulated to treat different sexually transmitted 
diseases. Fast dissolving films were made with PVA, 
HPMC E5 and propylene glycol and the produced 
films were applied intravaginally
84
. The results 
indicated that they can be used for the effective 
prevention of HIV infection. Olive oil based emulsion 
hydrogels have been produced for the treatment of 
sexually contagious disorders. In this case, sorbitan 
mono palmitate was added as a structuring agent. The 
resultant films were biocompatible and showed non-
Newtonian flow and can be used to prevent sexually 
transmitted infections
85
. Curcumin liposomes were 
prepared for the inhibition of vaginal infections. In this 
case mucoadhesive polymers like chitosan and 
Carbopol have been used to prepare the liposomes. 
Then different physiological properties including 
mucoadhesion strength were checked and it was 
revealed that the formulated mucoadhesive liposomes 
were useful as novel delivery system for vaginal 
infections
86. Mucoadhesive caplets of 3′-azido-3′-
deoxythimidine and polystyrene sulfonate (anti-HIV 
drug) were developed and characterized. Different 
mucoadhesive polymers like ethyl cellulose, 
polyacrylic acid have been used to prepare the caplet. 
The results proved that mucoadhesive caplets of the 
above drug can be used as potential drug delivery 
systems for treatment of HIV infected patients. 
Bio adhesive mini tablets were formulated and 
evaluated for the vaginal delivery of hexyl amino 
levulinate hydrochloride
87
. Different nonionic cellulose 
ethers and MCC were investigated as matrix forming 
agents.  The resultant mini tablets increased the 
residence time in the vaginal mucosa and therefore 
sustained release of the drug can be obtained. Novel 
silicone elastomer vaginal gels of maraviroc were 
developed and evaluated. The resultant gels were found 
to release the drug in a sustained manner. In a study, 
Cross linked Polyethylene glycol (PEG) based 
hydrogels of the antimicrobial subtilosin were 
developed and studied
88
. Characterization study proved 
that these hydrogels offered extended release of 
subtilosin for the prevention of bacterial vaginosis. 
Ethylene-vinyl acetate (EVA) copolymer vaginal rings 
containing progesterone were developed and evaluated. 
The rings having silicone were prepared by hot melt 
extrution method to release progesterone via the 
vagina. Solid lipid nanoparticles embodying antifungal 
drugs like ketoconazole, clotrimazole were prepared 
and evaluated. In this case PEG 40 stearate has been 
used and it reacted with acryloyl chloride to form a 
polymerisable moiety which produced a second shell 
for slow release of drugs
89
. Then in vitro studies of 
drug permeability revealed that the nano particles can 
be used for the inhibition of vaginal infections. 
UAMC01398, a diaryltriazinenon-nucleoside reverse 
transcriptase inhibitor was formulated as a gel and 
evaluated for anti-HIV microbicide activity. To 
produce the best formulation, different hydroxyethyl 
cellulose based gels were investigated to check their 
toxicity, stability, ability to enable UAMC01398 
epithelial permeation
90
. The result indicated that 
UAMC01398 has the potential to act as anti-HIV 
microbicide. Curcumin hydroxyl propyl cyclodextrin 
vaginal films have been formulated to treat cervical 
cancer caused by Human Papilloma Virus (HPV). In 
this case, solvent evaporation process was used to form 
the films by using HPMC E15 and carbopol 934P. It 
was concluded that these films offered longer residence 
time in vagina and have the potential to treat HPV 
induced cervical cancer
91
. Double reservoir 
polyurethane intravaginal rings were prepared to treat 
sexually transmitted diseases and uncontrolled 
pregnancy. Dual reservoir vaginal rings were designed 
in such a way that they will release tenofovir (HIV- 1 
reverse transcriptase inhibitor) and levonorgestrel 
(contraceptive) for a prolonged period. Oxybutynin 
vaginal rings for alleviation of overactive bladder 
symptoms in women have been developed. From the in 
vivo test it was revealed that these rings were well 
tolerated and have the potential to act as a novel drug 
delivery system for the prevention of overactive 
bladder symptoms. 
Lyophilized liposomal gels containing antiviral drug, 
acyclovir, for the intravaginal delivery were formulated 
and evaluated. Liposomes were prepared by rotary 
evaporation method with carbopol and HPMC and 
subsequently lyophilized. From the evaluation, it was 
revealed that the carbopol gels showed higher 
viscosity, spreadability and mucoadhesiveness than the 
HPMC gels, therefore carbopol liposomal gels were 
proposed as a promising delivery system of acyclovir 
via the vaginal route
92
. Fluconazole nanofibres have 
been developed for the management of vaginal 
candidiasis. Polymeric nanofibres consisting of the 
drug were formulated by electro spinning method. The 
resultant nanofibres were found to be effective offering 
sustained release of drug to treat vaginal infections. 
Electrospun solid dispersions of maraviroc were 
formulated and evaluated for constant intravaginal pre- 
exposure prophylaxis of HIV. The resultant solid 
dispersions have showed rapid release of maraviroc for 
the prevention of vaginal infections. 
 
METHODOLOGY IN EVALUATION OF 
VAGINAL DRUG DELIVERY SYSTEM
 
A vaginal detailing must be assessed by performing 
both in vitro and in vivo examines. Contingent upon the 
measurement frame, extra tests for vaginal medication 
items may incorporate appearance, thickness, pH, 
molecule estimate examination, disintegration rate, 
content consistency and microbial points of 
confinement
93
.  
In vitro studies 
 In vitro studies include the determination of drug 
release and bio-adhesive characteristics in addition to 
various physical and chemical properties of 
formulations. The discharge attributes of a medication 
from a vaginal detailing can be resolved in recreated 
vaginal liquid (pH 4.2) and in different disintegration 
media (pH go 2–12) by various sorts of dispersion cells 
with specific adjustments and a vaginal disintegration 
analyzer .The bio-glue quality of the vaginal definition 
can be measured by different strategies (like Wilhelmy 
plate surface strategy). 
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In vivo studies 
 In different animal models, in vivo studies are held for 
distribution, spreading, retention and to assess efficacy 
of formulations in the vagina. Assessing the 
distribution, spreading and retention of vaginal 
formulations in sheep and humans Gamma 
scintigraphy and colposcopy are desirable techniques. 
However, the significance of these findings is 
debatable. However Magnetic resonance imaging 
(MRI) and an intravaginal optic probe are the two 
techniques which are being developed to measure the 
degree of coverage in the vaginal vault. Various animal 
models such as sheep, rats, rabbits, rhesus monkeys, 
macaque monkeys, dogs and mice have been used in 
different studies in the development of vaginal 
formulations
93
. While white rabbits are used for 
primary irritation and sub chronic toxicity testing. 
Recently developed tissue model vaginal-ectocervical 
(VEC) will serve as a useful, highly reproducible, non-
animal tools to assess the irritation due to vaginal care 
product. 
 
CONCLUSION 
 Mucoadhesive vaginal drug delivery formulations 
offer potential improvements in residence time, 
bioavailability and penetration of drug through mucus 
membrane of vaginal cavity. It reduces the side effects 
that are caused by another route of drug administration 
like avoid first pass metabolism.  
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Table 1: Influence of age on the variation of pH, length, and width of human vagina 
Changes of vagina pH Length of vagina (cm) Width of vagina (cm) 
Before puberty 7 4.5-6 1-1.5 
Reproductive age 4-5 10 2.5 
Adult premenopause 4-5 7-8 2 
Post-menopause 4-7 4.5-6 1-1.5 
 
 
Table 2: The list of marketed vaginal products 
Brand Name Active Ingredients Application 
Replens® Polycarbophil Post menupousal atrophy
49
 
Vagifem® Estradiol hemihydrates Vaginal atrophy 
Zendol Danazol Endometriosis 
Nonoxynol-9 Nonoxynol-9 Contraceptive 
Nuvaring® Etonogestrel/ethinyl estradiol Contraceptive 
Nestorone® Ethinyl estradiol Contraceptive 
Gyne-lotrimin® Clotrimazole Vaginal yeast infections 
Monistat® Miconazole nitrate Vaginal yeast infections 
Crinone® Progesterone Infertility due to inadequate luteal 
phase 
Trivagizole® Clotrimazole Vaginal yeast infections 
Prochieve® Progesterone Progesterone deficiency 
Meprate® Medroxy progesterone acetate Endometriosis 
 
 
 
 
 
 
 
